Abstract Body

Background

HIV-specific broadly neutralising antibodies (bNAbs) have emerged as next generation paediatric interventions, with potential to prevent and treat HIV infection by neutralizing a wide spectrum of HIV-1 envelope (Env) glycoprotein variants. Neutralising breadth and potency against circulating strains can be enhanced by selecting appropriate bNAb combinations.

Methods

The LIFE study investigated preventive and therapeutic treatment strategies in neonates exposed to and diagnosed with HIV-1 from Mozambique and Tanzania. Pseudo virus particles (PVPs) neutralisation assays were developed to characterise single bNAb profiles from a panel of 8 monoclonal antibodies. We included 55 HIV-1 Env glycoprotein variants from vertical HIV-1 transmission cases, including recent isolates from the LIFE study in Mozambique and historical cases from Zambia and Rwanda. Infectivity of PVPs was quantified via luminescence readouts in relative light units (RLUs), and those demonstrating robust infectivity (>10⁶ RLUs) were selected for neutralisation assays. Half-maximal inhibitory concentrations (IC₅₀) were determined for each antibody against individual PVPs. Neutralisation was defined as a >50% reduction in RLUs relative to controls, with IC50 values estimated from dose-response curves.

Results

All bNAbs demonstrated inhibitory activity across a broad spectrum of HIV-1 Env variants, with potency increasing in a dose-dependent manner. Median IC₅₀ values for all bNAbs were below the potency threshold of 1 µg/ml (VRC01=0.21µg/ml; VRC07-523LS=0.05µg/ml; N6=0.08µg/ml; CAP256-V2LS=0.02µg/ml; PGT121.414LS=0.06µg/ml; 10E8v4-5RLS=0.63µg/ml; 10-1074=0.10µg/ml; PGDM1400LS=0.16µg/ml). Dual and triple antibody combinations targeting CD4 binding site (bs) and V3 glycans of the HIV-1 Env glycoprotein significantly decreased the IC₅₀ values (p<0.05). Of the two triple antibody combinations tested, Combo1: targeting CD4bs, V3, V1/V2 glycosylation sites (gs) and Combo2: targeting CD4bs, V1/V2 gs, MPERS gp41 subunit, both demonstrated significantly lower IC50 values compared to the dual combination (p=0.0096 and p=0.0004).

Conclusions

Selecting suitable bNAb combinations substantially enhanced suppression of diverse HIV-1 variants. Triple bNAb combinations were particularly effective, suggesting both the potency and the breadth of multi-bNAb regimens, and supporting their potential as preventative or therapeutic strategies for neonates at risk of vertical HIV-1 transmission.